Modulating IL-11-Dependent Matrix Stiffness To Delay Ovarian Aging
As women age, their ovaries undergo changes that can lead to a decline in fertility and overall ovarian health. One significant factor in this process is the stiffening of the ovarian tissue, which can impair its normal function. Recent research has shed light on a key player in this phenomenon: a protein known as Interleukin-11 (IL-11).
Scientists observed that levels of IL-11 increase in the ovaries of aging humans, mice, and rats. This elevated IL-11 then activates specialized cells called fibroblasts, which are responsible for producing the extracellular matrix (ECM). The ECM is essentially the scaffolding and connective tissue that surrounds and supports cells within an organ. When fibroblasts are overactive due to IL-11, they produce an excessive amount of ECM, making the ovarian tissue stiffer.
This increased stiffness has detrimental effects on ovarian function. It can hinder the proper development of follicles, which are the sacs containing eggs, and ultimately reduce fertility. The study demonstrated that by blocking the activity of IL-11—either through genetic modification or by administering tiny particles designed to interfere with IL-11—researchers could reduce ovarian stiffness in aged mice and rats. This intervention also led to improved ovarian function, balanced hormone levels, and enhanced fertility.
These findings suggest that targeting IL-11 could be a promising new strategy to delay ovarian aging and preserve reproductive health. This approach could potentially offer new therapeutic avenues for women experiencing age-related fertility decline or conditions like premature ovarian insufficiency and polycystic ovary syndrome, where ovarian stiffness is also a contributing factor.
Source: link to paper